Use tissue, compartment and accessible fuel to distinguish glycogen disorders, interpret diagnostic evidence and understand disease-specific care in original cases.
A large glycogen store can coexist with too little usable fuel. A child who cannot sustain blood glucose, an adult who cramps at the start of exercise and an infant with a failing heart may have defects in different reactions and compartments. Start with the job that failed. Then use the clinical pattern to test that explanation.
Identify the tissue, fuel problem and compartment
Before learning disease numbers, rebuild the normal route. Cytosolic glycogen contains alpha-1,4-linked glucose arms and alpha-1,6 branches. Phosphorylase releases most residues as glucose-1-phosphate using inorganic phosphate. Phosphoglucomutase produces G6P. Debranching uses transferase and glucosidase activities to clear branch limits, with the branch glucose released by hydrolysis. Synthesis uses UDP-glucose, glycogen synthase and a separate branching enzyme. PhosphorolysisSynthesisBranch creationTransferaseHydrolysis
Liver and kidney can release free glucose through the ER G6Pase system. Skeletal muscle lacks that physiologically important direct export system and uses G6P locally. Muscle glycogen can support glycolysis even while blood glucose is adequate. Lysosomes contain a separate glycogen pool that requires acid alpha-glucosidase, GAA. A working cytosolic phosphorylase does not replace a missing lysosomal enzyme. G1P/G6P conversionG6P hydrolysis
Make three predictions. With a fasting hepatic defect, look for impaired glucose availability between meals. With a muscle glycogen-use defect, examine when exertion becomes difficult. With a lysosomal defect, consider progressive tissue injury from compartmental accumulation. These are starting hypotheses. Hepatomegaly, weakness, CK elevation or PAS-positive glycogen are not individually sufficient to name an enzyme defect.
Choose a starting localization
Observed problem
Question to test
Observed problemFasting hypoglycemia
Question to testCan the liver access its reserve and release glucose?
Observed problemEarly exertional cramps
Question to testCan muscle use glycogen for rapid glycolysis?
Observed problemProgressive proximal or respiratory weakness
Question to testIs a lysosomal or other myopathic process present?
Observed problemLow glycogen without the usual enlarged liver
Question to testWas an adequate reserve synthesized?
Incoming free glucose is phosphorylated by hexokinase before joining the G6P pool. Phosphoglucose isomerase converts G6P to fructose-6-phosphate. PFK then uses ATP to make fructose-1,6-bisphosphate, so both fuel sources still require that shared reaction. Hexokinase reactionIsomerase reactionPFK reaction
For a concrete comparison, predict what happens when a normal glucose solution is supplied to two isolated muscle preparations. It can bypass muscle glycogen phosphorylase. It cannot bypass PFK, because glucose and glycogen both reach glycolysis upstream of that reaction. The later muscle diagram lets you test this prediction directly. These supplied-substrate experiments are original hypothetical teaching models, not clinical provocation instructions.
Does an enlarged liver prove usable glucose is available?
No. Material may accumulate upstream of a blocked reaction. The amount stored and the ability to deliver free glucose are separate questions.
Separate the final glucose exit from access to a reserve
In GSD I, glucose production encounters a shared final obstacle. GSD Ia usually involves G6PC1, encoding catalytic G6Pase. GSD Ib involves SLC37A4, encoding the ER G6P transporter. Both glycogenolysis and gluconeogenesis supply G6P upstream of this system. More amino acid substrate does not remove the final block, which is why protein alone cannot substitute for an individualized carbohydrate plan. GSD I
Locate the glucose-release failure
Hold cytosolic G6P supply constant. Compare an open route, lost catalysis and lost transport.
Both functions available. Transport delivers G6P to the ER reaction. Catalysis produces free glucose for export.
Which two requirements are separate? Substrate access and catalytic hydrolysis are separate requirements.
Ia catalytic defect. G6P can enter the compartment, but deficient catalytic hydrolysis impairs glucose release. Upstream material can accumulate.
Would opening the membrane replace missing catalysis? No. Access cannot substitute for the missing catalytic reaction.
Ib transport defect. The transport block prevents normal substrate access to the catalytic system. Opening a membrane can bypass this barrier in a hypothetical assay.
Does such rescue prove all patient manifestations? No. It localizes assay access while clinical and molecular evidence establish the disorder.
Original Bone Wizardry schematic, 2026. Qualitative teaching model. [12][26]
Compare catalysis with transport. Keep the G6P supply unchanged and select the two defects. In an original hypothetical microsomal assay, opening the membrane can restore access when transport is deficient. It cannot replace missing catalytic activity. The location of the rescue is mechanistic evidence; full diagnosis uses the phenotype and appropriate molecular evaluation.
Severe fasting hypoglycemia, hepatomegaly, lactate elevation, hyperlipidemia and hyperuricemia form a useful GSD I pattern. G6P is diverted toward other metabolic routes when glucose release is impaired. Increased lactate can impair renal urate handling, and altered purine metabolism also contributes to hyperuricemia. It is inaccurate to attribute urate production directly to the pentose-phosphate pathway alone. Ketones require context rather than an absolute “never present” rule. Ib can include neutropenia, recurrent infections and inflammatory bowel disease.
Management centers on reliable individualized carbohydrate availability, often including uncooked cornstarch and planned meals or feeds, plus illness planning. Glucose, lactate, lipids, growth and organ complications all matter. Allopurinol may be used for clinically indicated hyperuricemia; it does not restore G6Pase. Renal disease can include hyperfiltration and albuminuria before filtration falls. Hepatic adenomas require surveillance even after glucose control improves. A growing lesion needs reassessment rather than reassurance from one normal glucose result. Professional GSD I guidance
Fructose and galactose also supply carbon upstream of the final glucose-release defect in GSD I. They do not bypass it and can aggravate the metabolic load. Their restriction belongs in a dietitian-guided plan, alongside adequate nutrition rather than indiscriminate food avoidance. GSD I nutritional guidance
GSD Ib has a separate neutrophil-treatment question. A 2024 international consensus supports specialist use of empagliflozin for selected neutropenia or neutrophil dysfunction. It lowers the burden of a toxic glucose analogue metabolite; it does not replace the hepatic transporter. This use is off-label in the current US JARDIANCE label. Evidence remains limited, and glucose, hydration and adverse effects need close monitoring. The carbohydrate plan remains necessary. Original consensus recommendationsCurrent US label
GSD VI, or Hers disease, affects hepatic phosphorylase through PYGL. GSD IX affects phosphorylase kinase, with different subunit genes and tissue patterns. IX is not phosphoglycerate kinase deficiency. Their hepatic forms often present with ketotic fasting hypoglycemia, growth concerns, elevated transaminases and hyperlipidemia. Many courses are milder than classic GSD I, but fibrosis and other complications prevent a universal benign label. VI and IX guidanceKinase mechanism
During illness, high beta-hydroxybutyrate can signal inadequate accessible carbohydrate even if one glucose measurement is acceptable. Read glucose, ketones, intake and symptoms together and use the existing metabolic-team plan. GSD 0 offers the opposite storage problem. GYS2-associated hepatic synthesis deficiency can leave little glycogen, fasting ketosis and no typical glycogen-loaded hepatomegaly; post-meal glucose and lactate can rise. GYS1-associated muscle disease has a different phenotype. GSD 0
Distinguish a retained branch from a missing branch
A branch is useful during storage but requires extra work during mobilization. The AGL protein supplies transferase and alpha-1,6-glucosidase activities. In GSD III, their deficiency leaves glycogen with incompletely cleared outer branches, called limit dextrin. Contrast this with GSD IV, in which GBE1-associated branching deficiency can produce long, poorly branched polyglucosan material. These structures reflect different failures, not two names for the same glycogen. GSD IIIGSD IV
Compare synthesis architecture and digestion residue
Inspect the junctions and the outer arms. These diagrams show mechanisms, not tissue microscopy.
Normal branched glucan. Branches provide termini and can be cleared by the normal debranching system during degradation.
Does normal branching eliminate a need for debranching? No. The branch junction still requires its distinct clearing reactions.
III debranching defect. Short outer stubs remain when phosphorylase reaches its limit and debranching is deficient.
Is the original problem too few branches being created? No. The modeled problem is incomplete branch clearance during degradation.
IV branching defect. Poor branching during synthesis leaves unusually long segments with fewer junctions. This is a qualitative polyglucosan schematic.
Would adding debranching enzyme rebuild normal branching? No. Branch formation requires the synthetic branching reaction.
Original Bone Wizardry schematic, 2026. Qualitative teaching model. [13][14][3][5]
Inspect the architecture before naming the enzyme. Select the structure that contains short retained stubs after degradation. Then compare the structure with too few branch junctions before degradation. Adding debranching activities can rescue the first pattern in an isolated-substrate model. It does not rebuild the original branching pattern of the second.
GSD III commonly causes childhood hepatomegaly and ketotic fasting hypoglycemia. Gluconeogenesis and the final glucose-release system remain usable, supporting a different nutritional role for glucogenic protein than in GSD I. Lactate and urate are often less striking than in classic untreated GSD I, but single normal or abnormal values should not become categorical diagnostic rules. Specialist-directed protein and cornstarch plans address accessible fuel, not genetic correction.
GSD IIIa includes liver and muscle involvement, potentially including cardiomyopathy and progressive skeletal myopathy. IIIb is liver restricted. A normal childhood strength examination or CK result does not guarantee a lifelong liver-only course. Liver fibrosis and cirrhosis can occur, so improvement in childhood hepatomegaly does not end follow-up.
Classic progressive hepatic GSD IV can cause fibrosis, portal hypertension and liver failure. Hepatic progression varies; the 2023 clinical practice resource cautions against treating historical progressive/nonprogressive categories as fixed prospective predictions. Adult polyglucosan body disease can combine neurogenic bladder, spastic leg weakness and peripheral neuropathy. Neuromuscular presentations therefore extend across ages. Hypoglycemia may become prominent with advanced liver dysfunction rather than serving as an obligatory early feature. A transplant can replace hepatic function while the inherited defect remains in extrahepatic tissues. That explains why cardiac or muscle assessment can still matter afterward. Specialist assessment of actual hepatic deterioration and other organ involvement guides transplant decisions; the gene label alone does not require preemptive transplantation. GSD IV clinical practice resource
The drawings are original mechanistic schematics. They are not histology and cannot teach how a real biopsy looks. Glycogen staining by itself is also not a unique enzyme diagnosis. Clinical interpretation combines actual tissue findings, biochemical information and appropriate genetic testing.
Which defect preserves branch junctions but prevents complete clearing?
Debranching deficiency in GSD III retains branch-adjacent material. Branching deficiency in GSD IV creates an abnormal architecture during synthesis.
Use exercise timing and the point of fuel entry
GSD V, McArdle disease, results from PYGM-associated muscle phosphorylase deficiency. Symptoms often begin early in exercise, when rapid access to muscle glycogen is useful. Cramps, contractures and rhabdomyolysis can occur. The second-wind phenomenon describes improved tolerance with later availability and use of blood-borne fuel, particularly during appropriate aerobic activity. It does not mean the missing enzyme has regenerated within minutes. GSD V
Test whether blood glucose bypasses the defect
Keep blood glucose entry available. Compare the location of the two muscle pathway defects.
Both routes available. Glycogen and circulating glucose enter above the shared PFK-dependent glycolytic route.
Where do both routes converge? They converge at G6P upstream of PFK.
V phosphorylase defect. Blood glucose can enter below the PYGM-dependent glycogen step. Its availability can support later tolerable aerobic work.
Did the missing phosphorylase regenerate? No. An alternative fuel entry route remains available.
VII PFK defect. Both carbon sources still encounter the PFK defect. Merely supplying glucose does not bypass it.
Why does the PYGM bypass fail here? The PFK block lies downstream of both input routes.
Original Bone Wizardry schematic, 2026. Qualitative teaching model. [16][17][40][31]
Supply glucose to each pathway model. In the PYGM model, circulating glucose enters downstream of glycogen phosphorolysis and can support glycolysis. In the PFKM model, both glycogen and glucose still encounter the deficient PFK reaction. That is why a carbohydrate strategy useful for selected planned exercise in McArdle disease cannot be generalized to Tarui disease.
GSD VII, Tarui disease, affects muscle-type phosphofructokinase. Myopathy can occur with hemolysis because erythrocytes contain PFK forms incorporating M-type subunits. Red cells also contain other subunit combinations, so “all erythrocyte PFK is absent” is not an accurate general statement. A primary patient enzyme study demonstrated the subunit-specific defect. PFK patient study
During supervised non-ischemic forearm testing, some glycogenolytic or glycolytic defects blunt the lactate rise relative to ammonia. Ammonia can arise through AMP deamination; it does not prove normal glycolysis. Similar responses can arise from different defects. Modern evaluation favors appropriate molecular confirmation, with enzyme studies when indicated. Do not prescribe ischemic exercise as a casual diagnostic challenge.
Dark urine after exertion is also not unique to McArdle disease. Episodes after prolonged activity, fasting or illness with a preserved forearm lactate response broaden the differential toward other metabolic myopathies, including fatty-acid oxidation disorders. The pattern helps select further evaluation without establishing a particular disorder.
In confirmed McArdle disease, individualized gradual aerobic activity can be beneficial. Severe pain or sustained contracture is a reason to stop, not a training target. A small crossover study supports pre-exercise sucrose in selected circumstances, but it does not establish unlimited sugar use or a universal protocol. Heavy exertion followed by muscle pain and heme-positive urine with few red cells raises concern for myoglobinuria and rhabdomyolysis. Urgent assessment includes CK, renal function and electrolytes. Original exercise-substrate study
Why does flat lactate fail to distinguish V from VII by itself?
Both an upstream glycogen-mobilization defect and a downstream glycolytic defect can reduce lactate formation. Hemolysis, second wind and confirmatory testing provide additional discriminating information.
Recognize lysosomal disease across ages
Pompe disease, GSD II, results from deficient lysosomal acid alpha-glucosidase. Its compartment is central to the explanation. Increasing cytosolic phosphorylase does not supply the acid hydrolase inside lysosomes. Glycogen accumulation, lysosomal dysfunction and secondary cellular injury can impair muscle function even when a cytosolic glycogen assay appears intact. Pompe disease
Change lysosomal clearance without changing cytosolic flux
Compare GAA availability while the separate phosphorylase route remains drawn as functional.
GAA available. Lysosomal GAA permits glycogen hydrolysis in its compartment. Cytosolic phosphorolysis is a separate route.
Does one enzyme perform both reactions? No. GAA and phosphorylase have distinct reactions and compartments.
GAA deficient. More symbolic glucose residues occupy the lysosome when hydrolysis fails. The cytosolic route remains available in this simplified comparison.
Does the diagram predict a measured treatment outcome? No. It illustrates compartmental accumulation, not patient response magnitude.
Original Bone Wizardry schematic, 2026. Qualitative teaching model. [18][19]
Compare the two compartments. Select GAA deficiency while leaving cytosolic mobilization available. The drawing adds stored material inside the lysosome. Returning GAA activity reduces that modeled pool. This illustrates biochemical target engagement only. It does not simulate a measured treatment response or guarantee recovery of established tissue injury.
Classic infantile-onset Pompe can present with hypotonia, weakness, feeding difficulties, macroglossia, cardiomegaly and hypertrophic cardiomyopathy. A short PR interval can occur. The untreated natural history can be severe, but an untreated prognosis must not be presented as the inevitable outcome under modern therapy. Later-onset disease commonly emphasizes proximal weakness and respiratory muscle involvement, sometimes before major limb symptoms. Absence of the classic infantile cardiac pattern does not exclude it.
Inspect the real radiograph. Find the broad cardiac silhouette, then state the limit of the observation. The source describes increased cardiothoracic ratio on a PA chest radiograph. It does not identify the person as having Pompe disease. A chest image can show cardiac enlargement; it cannot establish GAA deficiency, and projection and clinical context matter. Echocardiography and disease-specific evaluation answer different questions.
Confirmation uses appropriate GAA activity testing and molecular evaluation in the clinical context. A single abnormal newborn screen is not a complete diagnosis. Pseudodeficiency variants can lower activity against artificial assay substrates without causing clinical Pompe disease. Likewise, one pathogenic allele plus a variant of uncertain significance does not automatically establish a recessive molecular diagnosis. Variant classification, allele arrangement and corroborating evidence matter.
Before enzyme replacement, CRIM assessment asks whether cross-reactive endogenous GAA protein is present. It is different from measuring sufficient catalytic activity. CRIM-negative infants have particular concern for sustained antibodies to the infused enzyme. Specialized immune-tolerance approaches may accompany prompt therapy. Infusion reactions and anaphylaxis remain material treatment risks requiring the appropriate clinical setting.
Match the intervention to the defect and the patient
Three treatment ideas should remain separate. A nutrition plan supplies usable substrate when an accessible route remains. Exercise planning matches demand to available fuel and protects injured muscle. Enzyme replacement supplies a specific deficient protein to its intended compartment. None is a generic treatment for every glycogen disorder.
In the United States, alglucosidase alfa, LUMIZYME, is indicated for Pompe disease. Avalglucosidase alfa-ngpt, NEXVIAZYME, is indicated for patients at least one year old with late-onset Pompe disease. Cipaglucosidase alfa-atga, POMBILITI, is used with miglustat, OPFOLDA, for adults with late-onset disease who weigh at least 40 kg and are not improving on current enzyme replacement. These label boundaries were checked for this remaster; eligibility does not establish an individual’s preferred regimen. LUMIZYME labelNEXVIAZYME labelPOMBILITI label
Test the boundary. An adult weighing 72 kg who is not improving on existing ERT fits the described POMBILITI population for consideration with miglustat. An untreated infant does not fit that same indication merely because both patients have GAA deficiency. The distinction uses age, weight, prior response and the required companion drug, rather than a drug-name association alone.
Clinical surveillance remains disease specific. Hepatic glycogen disorders can require growth, nutrition, metabolic, renal and liver assessment. Muscle-associated disease can require cardiac and respiratory assessment as well as strength evaluation. A single improving laboratory value does not establish that every organ is stable. Molecular diagnoses support family counseling; many of these disorders are autosomal recessive, while some phosphorylase-kinase disorders are X-linked.
Do not use unsafe or overly definitive shortcuts. GSD I glucagon stimulation can worsen metabolic acidosis and is not recommended to establish its diagnosis. A laboratory substrate rescue, an exercise lactate pattern or a clinical photograph does not establish a full patient diagnosis by itself. Experimental gene or substrate approaches should not be described as established treatment without current indication-specific evidence.
Return to the first three questions whenever a case becomes crowded. Which tissue is failing? Is the problem obtaining fuel, exporting glucose or clearing a compartment? Which alternative route remains available? The companion Glycogen metabolism lesson develops the synthesis, energy accounting and hormonal prerequisites, including UDP-glucose, glycogenin, insulin, allostery and fasting turnover. Activated donorPrimerSynthase allosteryInsulin signalingFasting fluxPhosphorylase regulation
These original cases ask for a mechanism, bounded interpretation or management consequence. All hypothetical assays are labeled. Use each option’s complete rationale and small reasoning questions to identify why a competing explanation fits or fails. No score or required sequence controls your access to the explanations.
Case 1
Show answer and explanations for case 1
A. Glycogen carbon bypasses G6P, but amino acid carbon must pass through it (Why this does not fit)
It releases G1P rather than free glucose. G1P becomes G6P, which requires the deficient hydrolytic step. Most glycogen-derived glucose equivalents remain phosphorylated until G6P hydrolysis.
B. Both carbon sources bypass G6P, but insufficient hepatic glycogen prevents their use (Why this does not fit)
GSD I commonly produces glycogen and fat accumulation. Stored material can accumulate upstream of an export block. This disorder accumulates hepatic glycogen despite failure to release adequate glucose.
C. Amino acid carbon bypasses G6P, but glycogen carbon must pass through it (Why this does not fit)
Its final hepatic hydrolytic step uses G6P. Additional substrate does not restore G6Pase activity. Gluconeogenesis does not provide a separate final glucose-export reaction.
D. Glycogen and amino acid carbon both encounter the blocked G6P-to-glucose reaction (Best answer)
Glycogen breakdown supplies G6P through G1P. It also reaches G6P before free-glucose release. Protein alone cannot restore the deficient final reaction. Substrates upstream of a shared block do not bypass it.
Takeaway: Glycogenolysis and gluconeogenesis share the final hepatic glucose-release reaction.
A. Deficient catalytic G6Pase activity in the endoplasmic reticulum (Why this does not fit)
Substrate gained direct access to the microsomal interior. Substantial catalytic G6P hydrolysis remains available. A catalytic defect would not be corrected merely by opening the membrane.
B. Deficient G6P transport into the endoplasmic reticulum (Best answer)
The G6P transport barrier is bypassed. SLC37A4-associated GSD Ib can include neutropenia and infections. The assay localizes access failure and the neutropenia supports the Ib phenotype.
C. Deficient lysosomal acid alpha-glucosidase activity (Why this does not fit)
G6P hydrolysis was tested in ER-derived microsomes. The restoration localizes an ER transport limitation instead. GAA hydrolyzes lysosomal glycogen rather than controlling ER G6P access.
D. Deficient cytosolic glycogen debranching activity (Why this does not fit)
The assay supplied G6P directly. It would not restore that separate cytosolic reaction. Debranching is upstream of the G6P substrate supplied directly in this assay.
Takeaway: An intact enzyme can fail when its substrate cannot reach it.
A. Confirm the filtration trend with an independent renal assessment and interpret it alongside persistent albumin loss (Best answer)
Repeated first-morning albuminuria supports a renal abnormality beyond an isolated postural or exercise-related result. A fall from hyperfiltration can accompany renal injury, although these estimates alone do not establish its mechanism or severity. Independent assessment of filtration together with the albumin trend can distinguish apparent normalization from a concerning renal trajectory. A filtration estimate returning from hyperfiltration into the reference range is not, by itself, evidence of renal recovery.
B. Repeat urine testing after daytime activity to determine whether orthostatic albumin loss explains the trend (Why this does not fit)
Albumin remained elevated in repeated first-morning urine samples. Daytime-only protein loss with normal first-morning urine would make a postural explanation more plausible. Persistent first-morning albuminuria already argues against a purely orthostatic explanation.
C. Continue albumin monitoring at the usual interval, treating the reference-range filtration result as recovery (Why this does not fit)
Improving albumin loss accompanying stable filtration would be more reassuring than rising albumin loss. The proposal does not test whether the fall from prior hyperfiltration reflects a worsening process. The direction of change and the concurrent albumin trajectory must be interpreted together.
D. Repeat the measurements after recovery from transient illness before assessing a persistent renal process (Why this does not fit)
The stem excludes a recent febrile illness and supplies persistent abnormalities on repeat sampling. GSD I renal involvement can persist despite improved glycemic control. An illness-related transient abnormality needs a corresponding time course.
Takeaway: Compare renal trajectories, not just the current reference range; persistent albumin loss needs its own evaluation.
A. Advance the next glucose-profile review and use its result to decide whether lesion imaging is needed (Why this does not fit)
A glucose profile assesses metabolic control rather than the structure of the hepatic adenoma. Interval lesion growth already warrants specialist reassessment. Glucose control does not characterize a growing hepatic lesion.
B. Keep the previous imaging interval because the recent metabolic trend is favorable (Why this does not fit)
Metabolic control improved during the last year. The adenoma enlarged despite that improvement. An earlier surveillance interval may need reconsideration when the lesion itself changes.
C. Arrange specialist reassessment of the enlarging lesion while continuing the metabolic plan (Best answer)
Normal fasting glucose describes current glucose control. Interval growth establishes a structural change that needs reassessment, not a particular histologic diagnosis. Metabolic and structural surveillance answer different clinical questions.
D. Proceed directly to treatment for malignant transformation on the basis of interval growth (Why this does not fit)
The stem identifies an adenoma with interval growth, without evidence establishing malignancy. Specialist lesion reassessment is needed to determine the appropriate subsequent management. Growth raises concern but does not by itself establish malignant transformation.
Takeaway: A growing adenoma needs reassessment even when glucose control improves.
A. A should increase glucose release substantially; B should remain limited (Why this does not fit)
Glycerol-derived carbon must reach G6P before hepatic free-glucose release. B releases glucose from alanine, whereas A accumulates G6P without adequate release. Supplying carbon upstream of G6P does not bypass A's demonstrated final-release limitation.
B. Both should increase glucose release substantially (Why this does not fit)
Ketone detection shows ketone availability in that sample, not preserved G6P-to-glucose capacity. A forms G6P from two sources but releases little free glucose. Detectable ketones do not establish that the final hepatic glucose-release system is intact.
C. B should increase glucose release substantially; A should remain limited (Best answer)
A's supplied-carbon results place the limitation at or after G6P formation in the glucose-release pathway. B retains gluconeogenic glucose release despite poor access to glycogen carbon. Glycerol should supply glucose through B's preserved route, while A still encounters its downstream release limitation. A new gluconeogenic precursor can bypass deficient access to glycogen but still encounters the final glucose-release system.
D. Both should remain limited in glucose release (Why this does not fit)
B releases glucose when alanine supplies carbon. Glycerol enters gluconeogenesis without first being released from glycogen. A hepatic glycogen-access problem does not necessarily block gluconeogenesis.
Takeaway: Use the whole fuel and substrate pattern; ketone detection does not override direct evidence of limited final glucose release.
A. Repeat liver fibrosis assessment as the explanation for the new motor findings (Why this does not fit)
Progressive proximal motor difficulty and persistent CK elevation indicate a muscle process. Improved hepatic control does not establish that skeletal or cardiac muscle is unaffected. Hepatic follow-up remains relevant but does not replace evaluation of the new muscle-associated risk.
B. Update ECG and echocardiography for potentially unrecognized cardiac involvement (Best answer)
A normal childhood CK and strength examination cannot guarantee a lifelong liver-only course. The persistent proximal weakness and CK elevation support reassessing muscle involvement consistent with a IIIa phenotype. Cardiac involvement can accompany IIIa disease and requires assessment beyond a symptom report. New muscle involvement in AGL-associated disease changes the relevance of the IIIa cardiac phenotype.
C. Repeat CK after further rest before changing the cardiac surveillance schedule for the liver-only phenotype (Why this does not fit)
A normal childhood strength examination and the absence of cardiac symptoms can make retaining the earlier liver-only surveillance schedule while rechecking CK seem reasonable. Progressive difficulty rising from the floor and CK elevation persisting after a week without strenuous exercise support emerging muscle involvement despite improved hepatic control. Further CK follow-up can accompany neuromuscular evaluation, but these persistent muscle findings warrant updated cardiac assessment without waiting for another CK measurement after rest.
D. Prioritize urine albumin and filtration measurements for a renal cause of the new weakness (Why this does not fit)
No renal abnormality is supplied, whereas persistent CK elevation accompanies proximal motor difficulty. The emerging AGL muscle phenotype makes cardiac surveillance particularly relevant. The supplied findings favor evolving myopathy rather than a demonstrated renal explanation.
Takeaway: A childhood liver-only appearance can change; new muscle findings require renewed cardiac as well as neuromuscular assessment.
A. Amino acids increase glycogen synthesis, making the enlarged reserve the main source of fasting glucose (Why this does not fit)
Release from glycogen stalls in the supplied debranching-deficient preparation. Labeled alanine reaches newly released glucose through a preserved alternative route. Increasing an incompletely mobilizable reserve does not explain alanine-derived glucose release.
B. Amino acids mainly supply muscle oxidative fuel, so the observed benefit does not require hepatic glucose production (Why this does not fit)
Newly released glucose contains the alanine label. Direct use of amino acids as tissue fuel does not explain their carbon appearing in hepatic free glucose. The supplied endpoint specifically documents hepatic production of new glucose.
C. Glucogenic amino acids can use preserved gluconeogenesis and the final glucose-release system (Best answer)
The alanine tracer demonstrates preserved gluconeogenesis to released glucose. GSD I limits the final G6P-to-glucose system required by gluconeogenic carbon as well as glycogen carbon. The experiment does not set a protein dose, eliminate carbohydrate monitoring or predict an individual clinical outcome. Gluconeogenic substrate can support an available route without replacing the missing debranching activity.
D. Amino acids provide substrate for the final G6P hydrolytic reaction that is the primary defect in this child (Why this does not fit)
Glycogen degradation is incomplete, while alanine-derived free-glucose production persists. Additional substrate would not replace a deficient final G6P hydrolytic reaction. The observed alanine-derived glucose release argues that the final release system is usable.
Takeaway: Protein can support a preserved gluconeogenic route in GSD III; the plan still requires individualized carbohydrate and metabolic monitoring.
A. A: near-control release; B: near-control release (Why this does not fit)
Transferase exposes the single alpha-1,6-linked branch residue by relocating adjacent alpha-1,4-linked residues. A would also need usable alpha-1,6-glucosidase activity, which its controlled endogenous assay lacks. Transferase supplementation does not replace A's independently deficient alpha-1,6-glucosidase activity.
B. A: low release; B: low release (Why this does not fit)
The new experiment supplies an already branched normal limit dextrin. B retains alpha-1,6-glucosidase activity that can hydrolyze the exposed branch-linked glucose. B's synthesis defect does not remove its measured capacity to clear branches in an externally supplied normal substrate.
C. A: near-control release; B: low release (Why this does not fit)
A has low alpha-1,6-glucosidase activity on the same defined substrate used for control comparisons. Low branching activity does not prevent B's retained debranching system from acting on supplied normal branch residues. This prediction reverses the independently measured branch-clearing capacities.
D. A: low release; B: near-control release (Best answer)
A has abnormal pre-exposure structure and low endogenous transferase and alpha-1,6-glucosidase activities on controlled matched substrates. Added transferase makes relocated alpha-1,4 residues available to phosphorylase, but A still cannot efficiently hydrolyze the labeled alpha-1,6 residue. B receives preformed normal branches and retains the endogenous glucosidase needed to release their label as free glucose. Selective transferase rescue exposes branch residues but still requires endogenous alpha-1,6-glucosidase for their release.
Takeaway: A limit dextrin produced by phosphorylase alone is not a debranching diagnosis. Pretreatment structure, controlled endogenous activity and selective rescue answer different questions.
A. Increase glycogen synthase in the cytosol and measure branch density in newly synthesized glycogen (Why this does not fit)
Recipient muscle glycogen synthase is normal on the supplied defined-substrate assay. Usable branching activity remains deficient in the cytosol, despite activity detected after cell lysis. Increasing elongation does not put usable branching activity beside the cytosolic substrate.
B. Increase extracellular glucose and measure branch density in newly synthesized glycogen (Why this does not fit)
Recipient muscle retained abnormal branching while donor liver cells synthesized normally branched glycogen. Activity after cell lysis does not demonstrate that the added enzyme reached the cytosolic synthesis site. More glucose does not resolve separation of an active enzyme from its substrate.
C. Deliver the same active branching enzyme directly to the cytosol and measure branch density in newly synthesized glycogen (Best answer)
The controls support an intrinsic recipient-muscle branch-creation limitation despite adequate hepatic fuel supply. Lysis makes the sequestered active enzyme accessible to assay substrate, whereas lysosomal membranes separate it from cytosolic glycogen in intact cells. Verified cytosolic delivery should improve branching of new glycogen under the stipulated controls; it would not establish clinical recovery or correction of every existing deposit. A lysate assay removes compartment barriers that can still prevent an active enzyme from reaching its substrate in intact cells.
D. Increase delivery of the same enzyme into lysosomes and measure branch density in newly synthesized cytosolic glycogen (Why this does not fit)
Uptake is verified and the whole-cell lysate already has near-control branching activity. The added enzyme remains separated by membranes from the cytosolic substrate used for new glycogen synthesis. Increasing enzyme in the wrong compartment tests amount rather than substrate access.
Takeaway: A normal graft, normal nutrient supply and normal whole-cell activity can each coexist with deficient activity at the recipient-cell substrate site.
A. Arrange preemptive liver transplantation on the timetable established by the first sibling (Why this does not fit)
The second child has preserved synthetic function and no current evidence of hepatic decompensation. The child's own hepatic course and multisystem assessment should inform transplant consideration. A relative's progressive hepatic course does not by itself determine transplant timing.
B. Limit follow-up to neuromuscular function because it is the predominant current manifestation (Why this does not fit)
Limited current hepatic progression does not settle the future hepatic course. Individualized hepatic and extrahepatic follow-up remains necessary. A predominant presentation does not remove the need to assess other involved organ systems.
C. Use the first sibling's fibrosis trajectory to set the second child's predicted age of liver failure (Why this does not fit)
The siblings currently show different organ-predominant courses despite the shared disease category. One sibling's timeline cannot determine the other's age of liver failure. GBE1-associated disease has variable hepatic and neuromuscular courses.
D. Follow the second child's hepatic and neuromuscular trajectory and assess interventions from that course (Best answer)
The siblings have different current hepatic and neuromuscular manifestations. Preserved current liver function supports individualized surveillance rather than a gene-based preemptive transplant assumption. Individual phenotype and progression guide care within the variable GBE1 spectrum.
Takeaway: GBE1 identifies a disease spectrum; the patient's own organ trajectory guides assessment.
A. The phosphorylase activation system, consistent with an IX-level mechanism (Best answer)
The target phosphorylase retains usable catalytic capacity. It supplied the phosphorylation step that activates phosphorylase. Genetic and clinical evaluation are still needed to identify the specific disorder. The experiment localizes a mechanism but does not establish a full molecular diagnosis.
B. The branch-point alpha-1,6 hydrolytic reaction (Why this does not fit)
Purified phosphorylase kinase was added. It phosphorylates its target rather than hydrolyzing glycogen branches. Phosphorylation does not replace debranching hydrolysis.
C. The catalytic glucose-6-phosphatase reaction (Why this does not fit)
Glycogen phosphorylase activity increased. It does not directly test glucose-6-phosphatase. The rescue measured phosphorylase activity rather than glucose export.
D. Complete absence of catalytically usable hepatic phosphorylase, as in a severe PYGL defect (Why this does not fit)
It regained activity into the control range. Usable phosphorylase remains in the preparation. A missing or completely inactive target cannot be restored merely by adding its kinase.
Takeaway: Rescue can distinguish activation machinery from its target enzyme.
A. Prioritize R for urgent assessment for intravenous carbohydrate support; continue oral support for S (Why this does not fit)
R retains feeds while ketones decline. S repeatedly vomits the prescribed feeds. A falling ketone trend with retained feeds differs from rising ketosis with failed oral intake.
B. Prioritize both for urgent assessment for intravenous support because each has had an elevated ketone result (Why this does not fit)
R is retaining prescribed feeds and has a substantially lower ketone concentration. S has rising ketosis and cannot retain the prescribed carbohydrate support. An isolated previous ketone value does not replace assessment of the current trajectory and feeding response.
C. Prioritize S for urgent assessment under the illness plan, including intravenous support if needed; continue R's responding plan (Best answer)
A single target-range glucose does not establish adequate ongoing carbohydrate availability when ketosis is rising. R can retain feeds and is improving, while S cannot retain feeds and may need a different support route. The data establish neither acidemia nor an individual infusion prescription; urgent assessment follows the existing clinical plan. Glucose, ketone trajectory and the ability to deliver carbohydrate must be interpreted together.
D. Continue oral support for both and escalate when glucose first falls below the agreed target (Why this does not fit)
S has rising beta-hydroxybutyrate despite repeated attempts at carbohydrate feeding. Repeated vomiting makes delivery through that route unreliable. Waiting for hypoglycemia ignores both rising ketosis and failed carbohydrate delivery.
Takeaway: The glucose snapshot does not replace the ketone trajectory or assessment of whether carbohydrate support is reaching the child.
A. Deficient hepatic glycogen synthase (Best answer)
Its degradation is preserved. Hepatic glucan elongation remains impaired. It supports a liver-associated rather than generalized muscle synthase defect. The synthesis assay and tissue restriction support a hepatic reserve-formation defect.
B. Deficient hepatic G6P transporter (Why this does not fit)
It enters at cytosolic glycogen elongation. It does not require the ER glucose-release system. An ER export defect does not directly explain failed UDP-glucose incorporation with low reserves.
C. Deficient lysosomal acid alpha-glucosidase (Why this does not fit)
GAA does not catalyze that synthetic incorporation. Hepatic glycogen synthesis is abnormal in the supplied-primer assay. The experiment concerns cytosolic synthesis and a depleted hepatic reserve.
D. Deficient hepatic glycogen phosphorylase (Why this does not fit)
It would impair phosphorolytic mobilization of hepatic glycogen. Incorporation from UDP-glucose remains poor. The assay demonstrates preserved degradation of an added glucan.
Takeaway: A glycogen disorder can reflect too little storage.
A. Little glycogen-derived label, but substantial supplied-glucose label (Best answer)
The pattern favors impaired rapid access to local glycogen with later support from circulating fuels. Supplied glucose enters downstream of glycogen phosphorylase after phosphorylation by hexokinase. Supplied glucose can contribute to lactate even when glycogen-derived contribution remains low; this is a predicted assay result, not molecular confirmation. A circulating glucose route can remain usable when muscle glycogen mobilization is limited.
B. Little label from either glycogen or supplied free glucose (Why this does not fit)
A PFK-level limitation can restrict lactate production from both glucose and glycogen. Second wind without hemolysis favors a muscle glycogen-access limitation over the supplied Tarui-like alternative. Failure of both inputs would suggest a shared downstream glycolytic limitation rather than the favored bypass pattern.
C. Substantial label from both glycogen and supplied free glucose (Why this does not fit)
Both carbohydrate inputs can remain usable when exercise limitation lies outside their mobilization and glycolytic routes. The experiment tests a persistent local glycogen-access limitation despite later clinical improvement. Preserved use of both carbohydrate inputs would weaken the proposed local glycogen-access explanation.
D. Substantial glycogen-derived label, but little supplied-glucose label (Why this does not fit)
Glycogen-derived G1P can reach G6P without the free-glucose hexokinase step. The favored explanation depends on usable circulating glucose rather than preferential access to local glycogen. An input defect before free glucose reaches G6P would predict the reverse of the favored phosphorylase-bypass pattern.
Takeaway: Second wind suggests an available alternative fuel route; a tracer prediction can test whether local glycogen use remains limited.
A. Erythrocyte breakdown; prioritize hemolysis markers to explain hemoglobinuria (Why this does not fit)
Dipstick heme alone cannot distinguish those pigments. Marked muscle pain and sustained contracture after heavy exertion favor muscle breakdown. Hemoglobin can cause pigmenturia, but the dominant injury pattern points more directly toward muscle.
B. Muscle breakdown; urgently assess CK, renal function and electrolytes (Best answer)
Myoglobin can be released from damaged muscle. Rhabdomyolysis can cause kidney injury and electrolyte disturbances. The pigment pattern supports urgent evaluation but does not establish every cause by itself. Myoglobinuria after exertional injury raises concern for systemic and renal complications.
C. Urine concentration; prioritize specific gravity to explain the dark appearance (Why this does not fit)
Dark color alone does not identify its cause. Strong heme reactivity with few red cells and an exertional injury trigger require consideration of muscle pigment. Concentration may darken urine but does not fully explain the strong heme signal and painful contracture.
D. Glomerular bleeding; prioritize urine red-cell morphology to localize the lesion (Why this does not fit)
It would supply red cells visible on microscopy. Severe pain after sustained exertion supports muscle injury. The few intact red cells do not explain the strong heme reaction and muscle-injury trigger as well.
Takeaway: This pattern warrants urgent assessment without treating urine color as a unique diagnosis.
A. Preserved muscle PFK activity with selectively reduced erythrocyte PFK activity (Why this does not fit)
Muscle formation of fructose-1,6-bisphosphate from an available fructose-6-phosphate pool is markedly low under matched conditions. An erythrocyte-restricted finding would leave the muscle substrate crossover unexplained. An erythrocyte-restricted PFK defect would not explain the demonstrated muscle reaction limitation.
B. Markedly reduced muscle PFK activity with preserved M-containing erythrocyte PFK forms (Why this does not fit)
Preserved erythrocyte M-containing forms would not support the same M-subunit defect as the explanation of hemolysis. The combined muscle limitation and hemolysis favor impairment of M-type PFK contributions in both tissues. A muscle-restricted finding would fit the muscle assay but not unify the supplied erythrocyte involvement.
C. Markedly reduced muscle PFK activity with reduced erythrocyte activity and residual non-M PFK forms (Best answer)
Normal upstream delivery to fructose-6-phosphate with deficient fructose-1,6-bisphosphate formation supports a PFK-level limitation. Fructose-1,6-bisphosphate rescue demonstrates usable downstream machinery, not PFK localization by itself. Impaired M-type PFK can affect both muscle and erythrocytes while non-M erythrocyte forms retain activity; exact residual activity is not specified. The substrate crossover localizes the muscle reaction; tissue subunit composition predicts partial rather than universal erythrocyte PFK loss.
D. Preserved PFK activity in both tissues with a shared defect upstream of fructose-6-phosphate formation (Why this does not fit)
Downstream rescue alone would not distinguish PFK deficiency from another defect before the supplied substrate. Preserved glucose phosphorylation and G1P-to-G6P-to-fructose-6-phosphate conversion establish usable upstream supply; the independent crossover supports the specific PFK-level localization. Hemolysis together with erythrocyte M-containing PFK forms supports a shared subunit mechanism rather than a muscle-only input failure. An upstream entry limitation requires evidence of failed substrate delivery that is absent from these controlled results.
Takeaway: Downstream rescue demonstrates downstream capacity. Specific PFK localization needs the upstream controls and substrate crossover; erythrocyte isoforms determine the partial tissue effect.
A. Substantial glucose-derived lactate label in both R and S (Why this does not fit)
Hemolysis without second wind in S favors a PFK-related hypothesis. Free-glucose carbon still requires PFK to reach lactate. Free glucose bypasses glycogen phosphorylase but still requires downstream glycolysis.
B. Little glucose-derived lactate label in both R and S (Why this does not fit)
The muscle phosphorylase hypothesis favored for R preserves entry of supplied glucose downstream of phosphorylase. The follow-up verifies uptake and phosphorylation of the free-glucose input. A low exercise lactate response does not mean every carbohydrate entry route is unusable.
C. Substantial glucose-derived lactate label in R, but little in S (Best answer)
Second wind favors a glycogen-access limitation in R, while hemolysis without relief favors a muscle-type PFK limitation in S. Free glucose should bypass a phosphorylase limitation in R but still encounter the proposed shared glycolytic limitation in S. The predicted functional distinction would guide confirmation, not establish a genotype or exclude every alternative cause. The phenotype separates hypotheses that a shared exercise lactate response cannot distinguish.
D. Little glucose-derived lactate label in R, but substantial label in S (Why this does not fit)
R's second-wind pattern favors an available circulating-glucose route despite limited glycogen use. S's hemolysis and absent relief favor a PFK-level limitation affecting both carbohydrate inputs. This reverses the bypass relationship favored by the two phenotypes.
Takeaway: Use phenotype to separate hypotheses, then test a substrate route that makes different predictions; shared exercise lactate findings are not an etiologic diagnosis.
A. Prioritize a lysosomal myopathy workup because episodic dark urine indicates progressive respiratory-muscle disease (Why this does not fit)
Brief initial activity is relatively well tolerated, with episodes linked to prolonged activity or illness. Progressive proximal and respiratory weakness would make a lysosomal myopathy more prominent in the differential. The supplied time course does not describe a predominantly progressive proximal-respiratory myopathy.
B. Prioritize PYGM confirmation because recurrent pigmenturia outweighs the preserved lactate response and late timing (Why this does not fit)
Relatively preserved initial activity and a normal forearm lactate rise weaken the classic muscle phosphorylase hypothesis. Early exertional contractures, second wind and a blunted lactate response would make that alternative stronger. Pigmenturia is shared by several causes of muscle injury and does not override exercise timing and testing.
C. Prioritize evaluation of alternative metabolic myopathies, including fatty-acid oxidation disorders, using the prolonged-exertion and illness pattern (Best answer)
A preserved lactate rise provides evidence against the classic severe glycogen-to-lactate limitation proposed in the prior note. Prolonged exertion and illness make alternative fuel-use disorders, including fatty-acid oxidation disorders, relevant to directed evaluation. This pattern does not establish a particular fatty-acid oxidation defect or exclude every glycogen disorder. Preserved brief carbohydrate-pathway testing does not exclude a limitation during prolonged fuel demand.
D. Prioritize PFKM confirmation because the late exertional episodes indicate a shared glycolytic block despite the normal lactate rise (Why this does not fit)
The supervised forearm test shows a normal lactate rise. Hemolysis, absent second wind and an appropriate blunted glycolytic response would strengthen that hypothesis. A shared glycolytic block is less consistent with the preserved lactate response than with a blunted response.
Takeaway: Timing and preserved brief carbohydrate use redirect the differential; dark urine alone does not identify a glycogen enzyme.
A. Deliver active GAA inside the vesicles and measure increased free glucose (Best answer)
Normal vesicle pH and another lysosomal hydrolase argue against a general acidification failure as the explanation of the measured glycogen defect. Lysosomal GAA hydrolyzes glycogen to free glucose, so targeted active GAA should increase that product in the controlled preparation. A biochemical rescue would not complete the infant's diagnostic confirmation or guarantee cardiac recovery. The compartment and activity controls favor deficient lysosomal glycogen hydrolysis rather than a failure of acidification or cytosolic mobilization.
B. Deliver active phosphorylase to the cytosol and measure increased G1P from the enclosed pool (Why this does not fit)
The supplied cytosolic phosphorylase assay is normal. Intact vesicle membranes separate cytosolic phosphorylase from the accumulating glycogen pool. An active enzyme outside an intact vesicle does not gain access to its enclosed substrate.
C. Restore vesicle acidification and measure increased free glucose (Why this does not fit)
The vesicles have normal pH and retain a separate lysosomal hydrolase activity. An abnormal vesicle pH impairing multiple acid hydrolases would make acidification rescue relevant. Restoring a property that is already normal does not replace a deficient glycogen-hydrolyzing activity.
D. Deliver active branching enzyme to the cytosol and measure restored branching of the excess pool (Why this does not fit)
The stem supplies low acid-pH glycogen hydrolysis in vesicles, not a demonstrated deficit of branch formation. Verified cytosolic delivery does not establish access to glycogen enclosed by intact vesicle membranes. A cytosolic synthesis intervention does not directly test deficient hydrolysis inside intact lysosomes.
Takeaway: Localize the reaction within the affected compartment before predicting an enzyme-rescue product.
A. Measure GAA activity in an appropriate diagnostic specimen and pursue molecular confirmation if the biochemical result supports Pompe (Best answer)
Weak inspiratory pressures and positional breathing difficulty, without a parenchymal explanation, support respiratory-muscle involvement. The adult proximal-axial and respiratory pattern keeps later-onset Pompe relevant despite absent hypertrophic cardiomyopathy. Appropriate GAA activity testing and molecular evaluation can test that etiologic hypothesis; the phenotype and CK alone do not establish it. An adult proximal and respiratory myopathy can reflect later-onset Pompe without the classic infantile cardiac pattern.
B. Measure acetylcholine-receptor antibodies and prioritize neuromuscular-junction testing for a fluctuating transmission disorder (Why this does not fit)
The stem describes fixed weakness without fluctuation or ocular symptoms. Progressive proximal-axial weakness, CK elevation and respiratory-muscle involvement support a myopathic evaluation. A transmission disorder is a differential consideration, but the supplied pattern favors fixed myopathy.
C. Prioritize PYGM testing after non-ischemic exercise testing for an early-exertional glycogen-mobilization disorder (Why this does not fit)
Early exertional cramps, contractures, second wind or episodic muscle pigment release would strengthen that hypothesis. Fixed progressive weakness and respiratory-muscle dysfunction dominate the current presentation. The supplied trajectory is progressive respiratory and proximal weakness rather than predominantly early-exertional episodes.
D. Prioritize a fatty-acid oxidation evaluation for episodes of prolonged-exertional rhabdomyolysis (Why this does not fit)
The stem does not supply episodic pigmenturia or prolonged-exertional attacks. The fixed proximal-axial and respiratory myopathy should drive the first etiologic hypothesis while broader differential evaluation remains available. An episodic fuel-demand disorder fits a different dominant trajectory from the one supplied.
Takeaway: Respiratory-muscle localization and age-specific phenotype can keep Pompe relevant when an infantile cardiac feature is absent.
A. Repeat only the same screening assay and classify the infantile phenotype if the value is again low (Why this does not fit)
Pseudodeficiency can continue to produce low activity against the screening substrate. Diagnostic enzyme interpretation and the second allele remain unresolved. Repeating an affected screening measurement does not resolve pseudodeficiency or establish clinical subtype.
B. Arrange prompt diagnostic GAA evaluation and resolve the molecular findings in the clinical context (Best answer)
The variant can lower measured screening activity without establishing clinical Pompe disease. An unresolved second allele prevents a definitive recessive molecular interpretation from the supplied result. A low screen needs confirmation when pseudodeficiency and incomplete genotype remain possible.
C. Use parental segregation of the named pseudodeficiency variant as the decisive disease-confirmation test (Why this does not fit)
Family studies can contribute to molecular interpretation. Segregation of the named pseudodeficiency variant does not establish a pathogenic second allele or disease-level GAA deficiency. Inheritance of a pseudodeficiency variant does not by itself establish pathogenic enzyme deficiency.
D. Use serial echocardiography first and defer diagnostic enzyme evaluation until cardiac abnormalities appear (Why this does not fit)
A normal current cardiac examination describes the infant's current cardiac status. It does not distinguish pseudodeficiency from confirmed disease or justify deferring prompt confirmation. Current absence of symptoms or cardiac findings does not resolve an abnormal newborn screen.
Takeaway: Confirm an abnormal newborn screen promptly; repeat screening, pedigree information and cardiac imaging answer different parts of the evaluation.
A. Absent endogenous GAA increases concern for antibodies to the replacement protein (Best answer)
Detectable endogenous GAA protein is absent. It can recognize the replacement protein as an antigen. Sustained antibodies can impair treatment effectiveness and require specialist prevention or management. The immune plan addresses treatment-response risk.
B. The test measures lysosomal uptake receptors and predicts intracellular enzyme delivery (Why this does not fit)
Endogenous GAA protein is assessed. It does not measure lysosomal delivery receptors or uptake efficiency. CRIM status does not measure the receptor system that delivers infused enzyme.
C. The test quantifies residual catalytic activity and predicts the exact replacement dose (Why this does not fit)
It reports whether cross-reactive endogenous GAA protein is detectable. Protein detection and catalytic activity are different measurements. CRIM testing assesses detectable endogenous protein rather than an exact catalytic rate or dose requirement.
D. The test detects existing neutralizing antibodies and proves prior enzyme sensitization (Why this does not fit)
The first infusion has not occurred. It can inform concern for an immune response after replacement exposure. CRIM-negative status is not itself a test for existing anti-drug antibodies.
Takeaway: CRIM protein status informs immune risk but is not an antibody titer or a catalytic assay.
R improves beyond the earlier measurements after recovery, while S has persistent unexplained decline on current therapy. S meets the adult weight threshold of at least 40 kg and has a not-improving trajectory; R's recovered trajectory does not establish that condition, and T is below the weight threshold. Label fit supports specialist consideration of the combination, not a guaranteed clinical benefit or a mandated switch. The labeled prior-response condition requires interpreting longitudinal response rather than selecting an isolated low measurement.
B. R and S (Why this does not fit)
R's repeated post-recovery measurements exceed the pre-illness values. S has repeated deterioration without the supplied confounders that explain R's temporary nadir. This selection includes an adult whose recovered trajectory does not establish the not-improving condition.
C. S and T (Why this does not fit)
Both S and T have sustained decline on current enzyme replacement without a supplied intercurrent explanation. T weighs 38 kg, below the at-least-40-kg threshold in the current US indication. A not-improving trajectory does not replace the independent labeled weight requirement.
D. R, S and T (Why this does not fit)
R improved beyond the earlier measurements after recovery on repeated assessment. T's decline does not remove the separate 40-kg weight requirement. The population boundary requires considering both the response trajectory and the independent weight condition.
Takeaway: Separate an illness-associated nadir from sustained lack of improvement before applying the current combination-treatment population boundary.
A. Add labeled glucose during treatment and show less label entering newly synthesized glycogen (Why this does not fit)
Label added during treatment primarily identifies newly supplied carbon. Reduced synthesis or delivery could lower new incorporation without clearing resident lysosomal glycogen. Reduced incorporation measures reduced incoming material rather than hydrolysis of the pre-existing pool.
B. Track pre-labeled lysosomal glycogen after washout, measuring label loss and labeled free glucose at matched viable-cell counts (Best answer)
A lower endpoint pool can result from greater removal, reduced input or loss of cells carrying the material. Prelabeling and removing extracellular label allow the experiment to follow the resident lysosomal pool rather than new input. Labeled free-glucose formation supports hydrolysis, while matched viable-cell counts reduce cell-loss confounding; the result remains biochemical evidence. A controlled resident-pool tracer and its hydrolytic product distinguish clearance from reduced influx or cell loss.
C. Measure total glycogen and total protein per well and show proportional reductions in both (Why this does not fit)
Loss of glycogen-rich cells could reduce both glycogen and total protein per well. The result fails to track conversion of a defined resident lysosomal pool into hydrolytic product. A proportional reduction in cell-associated material remains compatible with cell loss.
D. Measure an increase in whole-culture free glucose without identifying its carbon source (Why this does not fit)
Whole-culture glucose can reflect medium input or other cellular pools. The experiment needs to connect loss of resident lysosomal glycogen to a corresponding hydrolytic product. Unlabeled whole-culture glucose does not identify the resident lysosomal pool as its source.
Takeaway: A smaller pool is not itself a flux measurement. Trace resident substrate and product while controlling input and cell survival; clinical benefit remains unmeasured.
A. Resolve the uncertain allele and phase, with phenotype-directed corroboration such as an indicated muscle enzyme assay (Best answer)
One disease-associated PYGM allele is established. The VUS does not yet establish a second pathogenic allele in the required recessive configuration. Variant interpretation, phase and appropriate functional or clinical corroboration can address the incomplete diagnosis. A pathogenic allele plus a VUS is not automatically a confirmed recessive molecular diagnosis.
B. Obtain parental phase alone and call the diagnosis established if the variants are in trans (Why this does not fit)
Trans phase would place the variants on different parental alleles. Trans phase would not by itself establish that the uncertain variant is pathogenic. Phase and pathogenicity are distinct questions.
C. Repeat sequencing to verify both variant calls and use technical confirmation as the decisive disease evidence (Why this does not fit)
Repeat sequencing could confirm that the reported variants are present. The uncertain variant's pathogenicity and its relationship to the phenotype would remain unresolved. Analytic confirmation of a variant does not establish its disease effect.
D. Use a blunted non-ischemic forearm lactate response as the decisive confirmation of PYGM deficiency (Why this does not fit)
Different glycogenolytic and glycolytic defects can blunt the lactate response. The response can support a pathway hypothesis while molecular or indicated enzyme confirmation resolves etiology. A physiologic carbohydrate-pathway response is not uniquely diagnostic of PYGM deficiency.
Takeaway: Allele phase, analytic validity and pathogenicity are separate; incomplete molecular findings need appropriate corroboration.
